The company is under pressure from investors to add new pipeline assets, but stronger than expected initial sales of Spinraza helped to assuage near-term growth concerns.
Biogen may have a new CEO at the helm, but the company doesn't appear to be wavering from its strategy of investing in the high-risk, high-reward field of neuroscience.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
BridgeBio reported $36.7m in Q1 2025 sales of its ATTR-CM drug Attruby, tripling consensus forecasts. Vyndaquel-maker Pfizer acknowledged the product’s impact during the quarter.
